Summary & Overview
CPT 95018: Sequential Incremental Drug and Biologic Skin Test
Headline: CPT code 95018: Sequential Incremental Drug and Biologic Skin Test for Immediate Allergic Response
Lead: CPT code 95018 identifies a sequential, incremental skin testing procedure used to determine immediate hypersensitivity to drugs and biological products. The test applies minute amounts of test substances in a controlled escalating or de-escalating sequence, with provider interpretation and a formal report.
CPT code 95018 matters nationally because drug and biologic allergy assessment is central to patient safety, medication selection, and avoidance strategies across outpatient and specialty settings. Accurate coding affects clinical documentation, claims adjudication, and tracking of allergy evaluation services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical intent of the code, typical sites of service, common billing modifiers referenced for this service, and discussion of where this procedure fits in allergy/immunology practice workflows. The publication summarizes reimbursement and coverage considerations at a high level, highlights billing documentation elements tied to interpretation and reporting, and outlines where additional payer-specific policy review is required.
This summary is designed for coding professionals, practice managers, and allergy/immunology clinicians who need a concise national view of CPT code 95018 and its role in immediate hypersensitivity evaluation.
Billing Code Overview
CPT code 95018 describes a sequential and incremental skin test used to identify immediate allergic responses to drugs and biological products. The procedure involves applying the test substance(s) in minute quantities that can be increased or decreased in a controlled sequence, and may include sequential addition of multiple substances. A qualified provider interprets the responses and prepares a report documenting findings.
-
Service type: Allergy skin testing with sequential incremental exposure to drugs and biologicals
-
Typical site of service: Outpatient clinic or ambulatory care setting where allergy testing is performed; may also occur in specialty allergy/immunology offices
Clinical & Coding Specifications
Clinical Context
A 28-year-old outpatient presents to an allergy clinic with a history of recurrent urticaria and suspected immediate-type hypersensitivity to multiple environmental and medication triggers. The allergist performs a sequential incremental percutaneous skin test using dilute extracts of suspected drugs and biologics, beginning with minute concentrations and progressively increasing quantities under direct observation. The procedure is performed in an ambulatory clinic procedure room with vital sign monitoring and emergency medications available. The provider interprets wheal-and-flare responses at standardized intervals, documents the test sequence and concentrations, assesses immediate reactions, and prepares a written report summarizing positive and negative responses and clinical implications for future drug exposure.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit is performed and documented separately from the skin testing encounter earlier or on the same day |
26 | Professional component | Use when reporting only the physician interpretation and report separate from technical administration (if technical component billed by facility) |
52 | Reduced services | Use when the skin testing procedure is partially reduced or not completed as planned |
53 | Discontinued procedure | Use when testing is started but halted due to a patient reaction or other medical necessity |
59 | Distinct procedural service | Use when skin testing is distinct from other procedures performed on the same day and not ordinarily reported together |
76 | Repeat procedure by same physician | Use when the same provider repeats the test during the same encounter due to technical failure or equivocal initial results |
78 | Return to operating/procedure room for a related procedure during postoperative period | Rare for ambulatory skin testing; use only if a related procedure is performed emergently after initial testing in a monitored setting |
22 | Increased procedural services | Use when time, technical skill, or complexity for the testing exceeds typical expectations and is documented |
52 | Reduced services | Use when fewer test substances or reduced concentration increments are performed than originally planned |
59 | Distinct procedural service | Use to indicate the testing is separate from other dermatologic or allergy services on the same day |
76 | Repeat procedure by same physician | Appropriate when initial sequential testing must be repeated during the same day |
78 | Return to procedure room | Use only if patient requires urgent additional testing or monitored intervention after the initial test |
00 | No modifier (unmodified procedure code) | Use when none of the specific modifiers apply and standard testing is performed |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207RH0000X | Allergy & Immunology | Common specialty performing percutaneous sequential incremental skin testing for drugs and biologics |
| 207K00000X | Dermatology | Dermatologists may perform skin testing for immediate hypersensitivity when evaluating cutaneous allergic conditions |
| 2084P0800X | Internal Medicine - Pulmonary Disease | Allergy testing sometimes performed by internists with allergy specialization or in multidisciplinary respiratory clinics |
| 2080P0201X | Pediatrics | Pediatric allergists perform age-appropriate sequential skin testing for suspected drug or biologic allergies |
| 207L00000X | Clinical Pharmacology | Clinicians involved in drug allergy evaluation and desensitization protocols may perform or interpret testing |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
T78.2XXA | Anaphylactic shock, unspecified, initial encounter | Relevant when testing follows a suspected immediate anaphylactic reaction to a drug or biologic |
T88.7XXA | Unspecified adverse effect of drug, initial encounter | Used when a patient has an adverse reaction to a drug and needs evaluation to identify immediate-type allergy |
L50.9 | Urticaria, unspecified | Frequently the presenting symptom prompting evaluation with immediate-type skin testing |
Z88.9 | Allergy status to unspecified drug, adverse effect status | Documents known or suspected drug allergy in the patient’s problem list and charts the context for testing |
Z51.82 | Encounter for therapeutic drug administration | Relevant when testing guides subsequent decisions about therapeutic biologic administration or desensitization |
R21 | Rash and other nonspecific skin eruption | Common presenting complaint that may prompt evaluation including sequential incremental skin testing |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
95018 | Percutaneous tests (e.g., scratch, puncture), sequential and incremental with drugs and biologicals; interpret and report | This is the billed primary test for sequential incremental drug/biologic skin testing and includes interpretation and reporting by the provider |
95024 | Intracutaneous (intradermal) tests with drugs and biologicals; sequential and incremental; interpret and report | Often performed when percutaneous testing is negative or when greater sensitivity is required; may follow 95018 in workflow |
95117 | Professional services for allergy immunotherapy not elsewhere classified | May be used for follow-up management when testing leads to immunotherapy planning (administration separate) |
99213 | Office or other outpatient visit for the evaluation and management of an established patient, low to moderate severity | Common E/M level billed on same day when a separate, documented clinical evaluation is provided in addition to testing (use with 25 if applicable) |
95044 | Percutaneous tests (e.g., scratch, puncture) with allergens (includes multiple tests), interpreted and reported | Used for standard allergen skin testing panels for environmental allergens; different application but may be performed in the same clinic visit |
99070 | Supplies and materials (e.g., drugs, biologicals) provided by the physician over and above those usually included | Use to report additional supplies or test-specific materials needed for sequential incremental testing when payer allows |